Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,122 total articles
Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (NASDAQ: SYRE), executed a series of stock transactions on June 25, 2026, selling 15,000 shares of company common stock. The sales generated approximately $1,307,000. These transactions occurred concurrently with the exercise of stock options for an equivalent number of shares. T…
Daniel Rabinowitz, Secretary and Chief Legal Officer at Natera, Inc. (NASDAQ:NTRA), completed a sale of 33,600 shares of common stock on June 24, 2026, realizing approximately $8.45 million. The transaction was executed under a Rule 10b5-1 trading plan established in December 2025, leaving Rabinowitz with a direct holding of 189,094 shares. This in…
Natera Inc. (NASDAQ: NTRA) director Herm Rosenman executed a sale of 16,530 shares of common stock, generating proceeds of $4,132,500. The transaction, reported via a Form 4 filing with the Securities and Exchange Commission, occurred on June 24, 2026. Rosenman sold the shares at $250.00 per share under a Rule 10b5-1 trading plan established on Dec…
Susan Brasse Insley, Chief Operating Officer at NextNav Inc. (NASDAQ: NN), completed a stock transaction on June 24, 2026, selling 2,370 shares for a total value of $40,601. The sale was executed under a Rule 10b5-1 trading plan established on August 19, 2025, with proceeds designated for tax withholding obligations related to vested equity awards.…
ImmunityBio (NASDAQ: IBRX) director Simon Barry J. has executed a significant divestment of company equity, selling 25,000 shares of common stock on June 24, 2026. The transaction, valued at $196,907, was conducted within a narrow price band between $7.875 and $7.885 per share, resulting in a weighted average sale price of $7.8763. This sale follow…
CoreWeave Inc. (NASDAQ:CRWV) Chief Strategy Officer Brian M. Venturo has executed a significant stock sale, divesting 76,924 shares of Class A Common Stock on June 24, 2026. The transaction, valued at approximately $7,793,608, was carried out under a Rule 10b5-1 trading plan established in November 2025. This insider activity unfolds against a back…
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Chairman, CEO and Interim CFO Quang X. Pham executed a series of stock sales totaling $33,919. The transactions were conducted under a pre-established trading plan and occur as the company navigates critical regulatory pathways for its lead drug candidate, CAD-1005. Recent corporate developments include FDA…
Caryn Seidman Becker, Chief Executive Officer and director of Clear Secure, Inc. (NYSE:YOU), recently completed the sale of 34,309 shares of Class A Common Stock for $1,822,150. The transaction was processed on June 25, 2026, at a weighted average price of $53.11 per share, with individual sales ranging from $53.00 to $53.44. The sale was executed …
Alclear Investments, LLC, a significant stakeholder and board member of Clear Secure, Inc. (NASDAQ: YOU), has executed a substantial divestment of company equity. The transaction, processed through an automated trading plan, involved the sale of Class A Common Stock and a complex series of share class conversions. Concurrently, the company has repo…
Aaron Tachibana, serving as both Chief Financial Officer and Chief Operating Officer at Personalis, Inc. (NASDAQ: PSNL), executed a substantial divestment of company equity on June 26, 2026, selling 51,251 shares for approximately $675,488. The transaction was conducted under the parameters of a Rule 10b5-1 trading plan, which Tachibana established…
Jay S. Stout, Chief Technology Officer at Immunovant, Inc. (NASDAQ: IMVT), executed a significant divestment of company equity on June 26, 2026. The transaction involved the sale of 40,000 shares, generating total proceeds of $1,532,309. This executive selling activity occurs against a backdrop of robust stock performance, with shares trading near …
Andrew Pardo Wright, a director at Slide Insurance Holdings, Inc. (NASDAQ: SLDE), has completed two separate transactions totaling $843,796 in common stock sales. Executed under a pre-arranged 10b5-1 trading plan, these divestitures took place on June 24 and June 26, 2026. The sales occurred while the company's stock demonstrated significant short-…
Personalis, Inc. (NASDAQ: PSNL) Chief Executive Officer Christopher M. Hall executed a significant transaction involving the sale of company shares on June 26, 2026. The sale, valued at $1,315,000, was conducted under a Rule 10b5-1 trading plan established in late 2025. This financial activity occurred while the company's stock was trading near its…
Immunovant's Chief Operating Officer, Melanie Gloria, executed a significant sale of company shares in late June, reducing her direct holdings as the stock trades near its 52-week high. Despite the insider selling, the pharmaceutical company has garnered positive attention from multiple financial institutions citing robust clinical trial results an…
Immunovant, Inc. (NASDAQ: IMVT) Chief Legal Officer Christopher Van Tuyl executed a significant stock sale on June 26, 2026, liquidating 17,824 shares for a total of $682,886. The transaction followed the exercise of stock options granted in April 2025 and occurred as the company's stock price approached its 52-week high of $39.28. This executive a…
Immunovant Inc. CFO Tiago Girao executed a significant stock sale on June 26, 2026, disposing of 10,000 shares for approximately $384,600. This divestment directly followed the exercise of stock options for the same volume of shares at a lower strike price. The transaction occurs against a backdrop of robust stock performance and positive clinical …
Immunovant director Atul Pande sold 1,500 shares of company stock on June 26, 2026, valued at $57,015, pursuant to a Rule 10b5-1 trading plan adopted in December 2025. The sale coincides with Immunovant's stock trading near its 52-week high of $39.28, marking a significant 137% gain over the past year. Despite the company's unprofitable status, rec…
Brian C. Stephenson, Chief Financial Officer of Faeth Therapeutics, Inc. (NASDAQ:FTH), completed the acquisition of 15,641 shares valued at $401,268. The transactions were executed on June 24 and June 26, 2026, with purchase prices ranging from $23.61 to $27.77 per share. These purchases were made through the Brian Stephenson Revocable Trust, where…
Omada Health CEO Sean P. Duffy sold 17,258 shares between June 24 and June 26, 2026, under a 10b5-1 plan adopted in March. The transaction occurred as the stock trades near $20.89, up 32% year-to-date, despite some valuation concerns. This follows Q1 2026 results showing a revenue jump of 42% to $78 million and an earnings surprise, alongside a pri…
Oak Valley Bancorp director Don Barton has executed a sale of 375 shares in the company, a transaction filed with the Securities and Exchange Commission that underscores routine corporate activity. The sale, conducted under a pre-arranged 10b5-1(c) plan, comes as the regional bank continues its long-standing practice of dividend growth and recent s…
Nayaab Islam, President and Chief Product Officer of StubHub Holdings, Inc. (NASDAQ:STUB), executed a sale of 25,080 shares of the company's Class A Common Stock on June 26, 2026. The transaction, valued at approximately $302,141, was processed under a pre-arranged Rule 10b5-1 trading plan established on March 15, 2026. Following the sale, Islam re…
Brett P. Monia, Chief Executive Officer of IONIS PHARMACEUTICALS INC (NASDAQ:IONS), sold approximately $6,825,523 worth of the company’s common stock between June 24 and June 26, 2026. These sales were executed at prices ranging from $78.4128 to $80.59 per share, pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. The transactions c…
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Executive Vice President of Research Eric Swayze completed a significant stock transaction on June 25, 2026, selling 10,602 shares of common stock. The sale, valued at $839,491, was executed under a Rule 10b5-1 trading plan established in March 2026. This financial activity occurs as Ionis Pharmaceuticals ad…
Steven L. Cook, Chief Financial Officer of Omada Health, Inc. (NASDAQ:OMDA), executed a series of stock sales totaling $55,145 over two days in late June 2026. The transactions, conducted under a 10b5-1 trading plan established in March, reduced his direct holdings to 166,359 shares. This activity follows a period of significant market movement for…
Craig Gracey, the Chief Accounting Officer at Omada Health, Inc., executed a sale of 2,083 shares of the company's common stock on June 24, 2026. The transaction, valued at $39,601, was conducted under a pre-established 10b5-1 trading plan. This event occurs against a backdrop of recent financial performance and analyst activity. Omada Health recen…
